查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1926853

无囊输液袋市场按产品类型、材料、应用、最终用户和分销管道划分－2026-2032年全球预测

Bladderless Infusion Bag Market by Product Type, Material, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年无囊输液袋市值为 5.3021 亿美元，预计到 2026 年将成长至 5.7604 亿美元，预计到 2032 年将达到 9.4521 亿美元，复合年增长率为 8.60%。

关键市场统计数据
基准年 2025 5.3021亿美元
预计年份：2026年 5.7604亿美元
预测年份 2032 9.4521亿美元
复合年增长率 (%) 8.60%

关于无囊输液袋技术、临床意义和采购因素的权威框架为策略决策奠定了基础。

无囊输液袋的出现，已成为静脉输液领域的突破性创新，重塑了医疗机构的供应链、临床实践和设备选择标准。这些产品优先考虑减少塑胶废弃物，并与现代输液通讯协定相容，同时提供替代材料配置，以解决人们对聚氯乙烯（PVC）基输液系统日益增长的担忧。随着医院和门诊医疗机构在永续性目标和预算紧张的压力下重新评估其采购重点，无囊输液袋的评估标准不仅包括临床适用性，还包括其生命週期环境影响和运作效率。

临床、材料和采购趋势的综合作用正在推动输液袋技术的策略转变，并重塑其应用路径。

临床实务、材料创新和监管等多种因素的共同作用，正在重塑无囊输液袋的市场格局。聚合物科学的进步拓展了非PVC替代品的选择范围，并推动产品重新设计，以满足患者安全、化学相容性和永续性的需求。同时，医疗系统正在调整服务模式，转向更便捷的门诊/流动治疗模式，这使得操作简便、稳定性好、处置限制少的输液产品显得尤为重要。

2025年将改变美国供应链筹资策略、库存计画和定价结构的进口关税和海关趋势

2025年美国关税趋势为无囊输液袋的製造商和经销商带来了复杂的商业性和营运挑战。进口关税和归类规则的变化可能会影响原材料（尤其是聚合物和添加剂）的采购决策，并改变海外生产与国内生产的比较优势。对于拥有垂直整合供应链的公司而言，关税波动可能促使它们在本地在地采购零件、实现供应商多元化，并重新评估合约条款，以保护利润率并确保持续向美国医疗保健客户供货。

一个细緻、细分化的观点，整合了产品设计、材料选择、临床应用案例、护理环境和通路，并与市场推广驱动因素保持一致。

要了解市场动态，需要对产品、材料、临床应用、终端用户环境和通路有清晰的认识。产品架构至关重要：从双腔配置到单腔和三腔系统，各种选择应有尽有，每种配置在剂量柔软性、混合便利性和储存特性方面都各有不同，这些都会影响临床医生的偏好和采购选择。材料成分同样重要。产品大致可以其是否使用非PVC替代品或传统PVC系统进行分类，即使在非PVC产品中，也会根据乙烯-醋酸乙烯酯共聚物和聚乙烯混合物的不同而进一步区分，这些混合物对化学相容性、生产过程和环境影响各不相同。

区域分析描绘了全球主要市场丛集的采购行为、监管多样性和临床应用途径

区域环境影响无囊输液袋的监管要求、采购行动和临床应用时间表。在美洲，负责人在成本控制和永续性倡议之间寻求平衡，这受到大规模综合医疗网络的影响，这些网络整合了采购力量，并实现了各医疗机构设备选择的标准化。这些趋势有利于那些能够证明其拥有严格的品质系统、稳定的供应保障以及在不影响临床疗效的前提下展现出环境效益的供应商。

一份深入的竞争评估报告，展示了产品创新、临床伙伴关係和稳健的分销模式如何创造永续的差异化优势。

无囊输液袋生态系统的竞争主要由材料和製造技术的创新、与临床网路的策略合作以及确保供应连续性的能力所驱动。领先的製造商优先投资研发，以优化聚合物配方，使其既满足临床相容性要求，又能降低环境影响，并不断改进生产工艺，以支持大规模生产并提高成本效益。相关人员的合作是产品推广应用的关键。那些资助同侪审查证据、真实世界应用研究和培训计画的供应商，通常能够更顺利地获得医院批准，并更快地被列入药品目录。

製造商和经销商应采取具体措施，确保临床应用，提高供应韧性，并使商业模式与当地采购优先事项保持一致。

为了将技术优势转化为持续的临床应用，产业领导者必须在产品开发、供应链韧性和相关人员参与等方面采取果断行动。投资于能够降低环境影响、同时又能证明化学相容性和患者安全性的材料研究，优先进行检验研究，并建立透明的材料文檔，将有助于加快临床认可和采购核准。同时，实现采购多元化，探索本地生产和契约製造，可以降低关税波动和物流中断带来的风险，并为关键客户提供更稳定的价格和更快的交货速度。

采用透明的多学科方法，结合临床医生访谈、监管分析和技术审查，得出可操作的结论和建议。

本研究结合了临床相关人员、采购负责人和供应链经理的访谈，并辅以对监管指南、生产实务和材料科学文献的二次分析。这种方法平衡了来自临床终端使用者和营运领导者的定性见解与聚合物性能和设备配置选项的技术审查。这种资讯来源的三角验证，能够提供反映住院、门诊和诊所实际运作的见解，确保策略建议既有文献证据支持，也有实务经验支撑。

清楚地总结了各项策略要务，阐明了临床证据、供应可靠性和区域一致性如何决定产品的采纳和长期价值。

无囊输液袋代表材料科学、临床实践和供应链策略交叉领域的转折点，它将影响医疗设备的采用和长期采购决策。虽然这项技术在某些医疗环境中具有显着优势，尤其是在环境影响、易用性和与门诊护理流程的兼容性是优先考虑因素的情况下，但其成功应用将取决于明确的临床等效性证据、可靠的供应保障以及与当地监管要求的契合度。那些投资于完善的检验、在地化供应链和有针对性的教育倡议的相关人员，将更有利于把产品创新转化为可重复的临床应用。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 无囊输液袋市场（依产品类型划分）

  • 双室
  • 单室
  • 三腔体

9. 无囊输液袋市场（依材料分类）

  • 非氯乙烯
    • 乙烯-醋酸乙烯酯
    • 聚乙烯
  • 聚氯乙烯

第十章 无囊输液袋市场依应用领域划分

  • 输血
  • 化疗
  • 水合作用
  • 静脉营养

第十一章 无囊输液袋市场（以最终用户划分）

  • 门诊治疗
  • 诊所
  • 医院

第十二章 无囊输液袋市场（依通路划分）

  • 批发商
  • 医院药房
  • 网路药房

第十三章 各地区无囊输液袋市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 无囊输液袋市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国无囊输液袋市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国无囊输液袋市场

第十七章 中国无囊输液袋市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • B. Braun
  • Baxter International
  • Fresenius Kabi
  • Grifols SA
  • Huaren Pharmaceutical Co. Ltd.
  • JW Life Science Corp.
  • Merck Millipore
  • PolyCine GmbH
  • Sealed Air Corp.
  • Sichuan Kelun Pharmaceutical
  • Technoflex SAS
  • Terumo Corporation
  • Wipak Walsrode GmbH
Product Code: MRR-4F7A6D4FF336

The Bladderless Infusion Bag Market was valued at USD 530.21 million in 2025 and is projected to grow to USD 576.04 million in 2026, with a CAGR of 8.60%, reaching USD 945.21 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 530.21 million
Estimated Year [2026] USD 576.04 million
Forecast Year [2032] USD 945.21 million
CAGR (%) 8.60%

An authoritative framing of bladderless infusion bag technologies, clinical relevance, and procurement drivers that set the stage for strategic decision-making

Bladderless infusion bags have emerged as a pivotal innovation within intravenous therapy delivery, reshaping supply chains, clinical practice, and device selection criteria across care settings. These products prioritize reduced plastic waste profiles and compatibility with contemporary infusion protocols while offering alternative material compositions that respond to escalating concerns about polyvinyl chloride-based systems. As hospitals and outpatient providers reassess procurement priorities under pressure from sustainability goals and tighter budgetary constraints, bladderless infusion bags are increasingly evaluated not only for clinical compatibility but also for lifecycle environmental impact and operational efficiencies.

This analysis frames bladderless infusion technologies in the context of their material science, configuration options, and clinical applications. It situates these devices within evolving regulatory expectations and procurement behaviors, underscoring how technical design choices influence handling, storage, and compatibility with existing infusion pumps and workflows. Moreover, the section highlights how service providers and distributors are adapting stocking strategies and inventory models to support widespread adoption while mitigating risk in sterile supply chains. By clarifying the core attributes and system requirements of bladderless infusion bags, this introduction establishes the foundation for deeper insight into market dynamics, regional nuances, and strategic imperatives for manufacturers, suppliers, and clinical leaders.

A synthesis of clinical, material, and procurement dynamics that are driving strategic shifts and reshaping adoption pathways for infusion bag technologies

The landscape for bladderless infusion bags is being reshaped by converging forces in clinical practice, material innovation, and regulatory scrutiny. Advances in polymer science have expanded viable non-PVC alternatives, catalyzing product redesigns that address patient safety, chemical compatibility, and sustainability expectations. At the same time, healthcare systems are reengineering care delivery toward more ambulatory and outpatient models, thereby elevating the importance of infusion products that offer simplified handling, robust storage stability, and fewer disposal constraints.

Shifts in procurement philosophies are also materializing: value assessment is moving beyond unit price to include total cost of ownership, environmental impact, and ease of integration into existing clinical protocols. This transition encourages suppliers to present comprehensive value propositions that bundle training, supply continuity guarantees, and compatibility assurances. Additionally, heightened regulatory emphasis on traceability and supply chain transparency is prompting manufacturers to invest in serialization, enhanced quality systems, and documentation to facilitate hospital credentialing and audit processes.

Taken together, these transformative trends are driving product differentiation along dimensions that matter most to clinicians and supply chain managers: material safety, clinical performance, environmental footprint, and assurance of supply continuity. As adoption pathways evolve, stakeholders who anticipate interoperability challenges and articulate clear evidence of clinical equivalence will be best positioned to translate innovation into routine use

How changes in import duties and customs practices are altering sourcing strategies, inventory planning, and pricing structures for U.S. supply chains in 2025

Tariff developments in the United States for 2025 introduce a complex layer of commercial and operational considerations for manufacturers and distributors of bladderless infusion bags. Changes to import duties and classification rules can influence sourcing decisions for raw materials, particularly polymers and additives, and may alter the comparative advantage of offshore versus domestic production. For companies with vertically integrated supply chains, tariff shifts create incentives to reexamine component localization, supplier diversification, and contract terms to protect margins and ensure uninterrupted supply to U.S. healthcare customers.

Moreover, tariff-related adjustments can affect inventory strategies; stakeholders may elect to increase buffer stocks or accelerate procurement to hedge against cost volatility, which in turn impacts warehousing needs and working capital. Payers and health systems, seeking predictable procurement costs, may push for longer contract terms or fixed-price agreements, prompting suppliers to incorporate tariff risk clauses or hedging mechanisms into their commercial models. Regulatory compliance and customs classification clarity become essential operational priorities to avoid unexpected duties and mitigate the risk of delayed clearances at ports of entry.

In response, many organizations are evaluating nearshoring and regional manufacturing partnerships to reduce exposure to tariff oscillations while improving lead times and quality control. Transparent communication with purchasing groups and supply chain partners, coupled with scenario planning for duty changes, will be critical to sustaining supply reliability and preserving competitive pricing structures in the U.S. clinical market

A nuanced segmentation-driven perspective that aligns product design, material selection, clinical use cases, care settings, and distribution channels with adoption levers

Understanding market dynamics requires a clear view of product, material, clinical application, end-user contexts, and distribution pathways. Product architecture matters: options range from double chamber configurations to single chamber and triple chamber systems, each offering different dosing flexibility, admixture convenience, and storage characteristics that influence clinician preference and procurement selection. Material composition is equally consequential; products are broadly categorized by their use of non-polyvinyl chloride alternatives versus traditional polyvinyl chloride systems, and among non-PVC choices there is further differentiation between ethylene vinyl acetate and polyethylene formulations, which carry distinct implications for chemical compatibility, manufacturing processes, and environmental profile.

Clinical application drives specification and adoption; bladderless systems are evaluated across blood transfusion, chemotherapy, hydration therapy, and parenteral nutrition use cases, where fluid compatibility, sterility assurance, and administration accuracy are paramount. The setting of care shapes operational requirements: ambulatory care sites favor compact, easy-to-handle formats that reduce disposal burden, clinics prioritize reusable compatibility with existing infusion technologies, and hospitals demand high throughput solutions that support efficient stocking and rapid deployment during complex procedures. Distribution channels determine availability and procurement dynamics; distributors play a central role in logistics and contract facilitation, hospital pharmacies manage clinical stocking and stewardship, and online pharmacies present an emerging channel for outpatient and home infusion access. By integrating these segmentation lenses, stakeholders can align product development and commercial strategies with the specific needs of each clinical and supply chain cohort

A regionally informed analysis that maps procurement behaviors, regulatory diversity, and clinical adoption vectors across major global market clusters

Regional context shapes regulatory expectations, procurement behaviors, and clinical adoption timelines for bladderless infusion bags. In the Americas, purchasers are balancing cost containment with sustainability initiatives and are influenced by large integrated delivery networks that consolidate purchasing power and standardize device selection across facilities. These dynamics favor suppliers that can demonstrate rigorous quality systems, robust supply continuity, and evidence of environmental benefits without compromising clinical performance.

Across Europe, the Middle East & Africa, regulatory diversity and varying reimbursement mechanisms produce heterogenous adoption patterns. In several European markets, policy drivers and hospital sustainability targets accelerate interest in non-PVC solutions, while in other markets procurement cycles and budgetary constraints can slow uptake. Middle Eastern and African healthcare systems often prioritize scalable, cost-effective options that can be integrated into centralized procurement frameworks, creating opportunities for regional distributors and manufacturers that can provide localized service and training.

Asia-Pacific presents a mixed picture with advanced tertiary centers in some countries adopting novel infusion technologies rapidly, while other markets prioritize cost and local manufacturing capacity. In fast-growing outpatient and home infusion segments, Asia-Pacific providers are especially sensitive to ease of use, storage stability in diverse climates, and alignment with evolving clinical protocols. Across all regions, successful commercialization requires tailored regulatory strategies, localized value messaging, and supply chain models that address regional logistics and procurement norms

An incisive assessment of competitive strategies showing how product innovation, clinical partnerships, and resilient distribution models create sustainable differentiation

Competitive dynamics within the bladderless infusion bag ecosystem are shaped by innovation in materials and manufacturing, strategic partnerships with clinical networks, and the ability to guarantee supply continuity. Leading manufacturers are prioritizing R&D investments that optimize polymer formulations to meet clinical compatibility requirements while reducing environmental impact, and they are refining production processes to support high-volume, cost-efficient output. Collaboration with clinical stakeholders is central to adoption; suppliers that fund peer-reviewed evidence, real-world use studies, and training programs typically see smoother hospital credentialing and faster inclusion in formularies.

Distribution and service models are evolving in parallel, with an increasing emphasis on value-added services such as inventory management, just-in-time delivery, and digital tools that enable traceability and usage analytics. Companies that can offer integrated solutions-combining product reliability with predictable logistics and actionable data-create differentiation in procurement conversations. Similarly, manufacturers pursuing regional manufacturing footprints or contract manufacturing arrangements are better positioned to mitigate tariff and transportation risks while meeting localized regulatory requirements. Overall, the competitive landscape rewards firms that balance technical excellence, operational resilience, and collaborative commercialization strategies with healthcare providers

Targeted actions for manufacturers and distributors to secure clinical adoption, improve supply resilience, and align commercial models with regional procurement priorities

Industry leaders should act decisively across product development, supply chain resilience, and stakeholder engagement to convert technical advantages into sustained clinical adoption. Invest in material research that demonstrates chemical compatibility and patient safety while enabling a lower environmental footprint; prioritized validation studies and transparent materials documentation will expedite clinical acceptance and procurement approval. Concurrently, diversify sourcing and explore regional production or contract manufacturing to reduce exposure to tariff fluctuations and logistics disruptions, enabling more stable pricing and shorter lead times for critical customers.

Engage early with clinical champions and procurement groups to co-design training, handling protocols, and inventory management workflows that minimize implementation friction. Offer bundled solutions that include demonstrable supply continuity commitments, education resources, and access to usage analytics to support hospital stewardship programs. Finally, tailor commercial approaches by region and care setting-align messaging with sustainability priorities in markets that emphasize environmental impact, emphasize ease of use in ambulatory and home infusion segments, and underscore cost predictability for large integrated health systems. These actions, taken together, will enhance market receptivity and support long-term partnerships with care providers

A transparent, mixed-methods approach combining clinician interviews, regulatory analysis, and technical review to underpin actionable insights and recommendations

This research synthesizes primary interviews with clinical stakeholders, procurement professionals, and supply chain managers, complemented by secondary analysis of regulatory guidance, manufacturing practices, and material science literature. The approach balances qualitative insight from clinician end users and operations leaders with technical review of polymer characteristics and device configuration options. Triangulation of sources ensures that findings reflect operational realities across inpatient, clinic, and ambulatory care environments, and that strategic recommendations are grounded in both documented evidence and practitioner experience.

Data integrity was maintained through cross-validation of interview themes with publicly available regulatory documents and manufacturer technical specifications, and by assessing distribution channel behaviors through conversations with logistics providers and hospital pharmacy leaders. Regional analyses incorporated policy review and stakeholder feedback to capture differences in procurement cycles and regulatory pathways. Throughout the methodology, emphasis was placed on capturing actionable intelligence for commercial and clinical decision-makers while avoiding speculative projections. The synthesis prioritizes transparency in source attribution and methodological rigor to support confident implementation of the insights presented

A clear synthesis of strategic imperatives showing how clinical evidence, supply reliability, and regional alignment determine adoption and long-term value

Bladderless infusion bags represent an inflection point where material science, clinical practice, and supply chain strategy intersect to influence device adoption and long-term procurement decisions. The technology offers tangible advantages in certain care contexts-particularly where environmental impact, ease of handling, and compatibility with ambulatory workflows are prioritized-but successful adoption hinges on clear evidence of clinical equivalence, demonstrated supply reliability, and alignment with regional regulatory expectations. Stakeholders that invest in robust validation, localized supply arrangements, and targeted education initiatives will be best placed to translate product innovation into repeatable clinical use.

Moving forward, the most effective commercialization strategies will combine technical credibility with operational assurance. Manufacturers and distributors that deliver consistent quality, partner with clinical leaders to generate real-world evidence, and structure distribution to minimize disruption will create durable advantages in competitive procurement environments. For healthcare providers and procurement organizations, the choice to adopt bladderless infusion systems should be informed by comparative assessments of material compatibility, lifecycle implications, and the provider's capacity to integrate new device workflows without compromising patient safety or operational efficiency. Taken together, the insights in this report aim to equip decision-makers with the context needed to navigate adoption thoughtfully and pragmatically

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bladderless Infusion Bag Market, by Product Type

  • 8.1. Double Chamber
  • 8.2. Single Chamber
  • 8.3. Triple Chamber

9. Bladderless Infusion Bag Market, by Material

  • 9.1. Non Polyvinyl Chloride
    • 9.1.1. Ethylene Vinyl Acetate
    • 9.1.2. Polyethylene
  • 9.2. Polyvinyl Chloride

10. Bladderless Infusion Bag Market, by Application

  • 10.1. Blood Transfusion
  • 10.2. Chemotherapy
  • 10.3. Hydration
  • 10.4. Parenteral Nutrition

11. Bladderless Infusion Bag Market, by End User

  • 11.1. Ambulatory Care
  • 11.2. Clinics
  • 11.3. Hospitals

12. Bladderless Infusion Bag Market, by Distribution Channel

  • 12.1. Distributors
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies

13. Bladderless Infusion Bag Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bladderless Infusion Bag Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bladderless Infusion Bag Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bladderless Infusion Bag Market

17. China Bladderless Infusion Bag Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. B. Braun
  • 18.6. Baxter International
  • 18.7. Fresenius Kabi
  • 18.8. Grifols S.A.
  • 18.9. Huaren Pharmaceutical Co. Ltd.
  • 18.10. JW Life Science Corp.
  • 18.11. Merck Millipore
  • 18.12. PolyCine GmbH
  • 18.13. Sealed Air Corp.
  • 18.14. Sichuan Kelun Pharmaceutical
  • 18.15. Technoflex SAS
  • 18.16. Terumo Corporation
  • 18.17. Wipak Walsrode GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLADDERLESS INFUSION BAG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLADDERLESS INFUSION BAG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DOUBLE CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DOUBLE CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DOUBLE CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY SINGLE CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY SINGLE CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY SINGLE CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY TRIPLE CHAMBER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY TRIPLE CHAMBER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY TRIPLE CHAMBER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ETHYLENE VINYL ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYETHYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYETHYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYETHYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYVINYL CHLORIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYVINYL CHLORIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY POLYVINYL CHLORIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY BLOOD TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY BLOOD TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HYDRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HYDRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HYDRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY PARENTERAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY PARENTERAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 127. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 128. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. GCC BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 148. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. G7 BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 155. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 156. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. NATO BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BLADDERLESS INFUSION BAG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY NON POLYVINYL CHLORIDE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA BLADDERLESS INFUSION BAG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)